

Diabetes & Obesity

RESEARCH REVIEW™

Making Education Easy

Issue 144 – 2021

In this issue:

- 1- vs. 2-step GDM screening
- Prediabetes prevalence and associated factors in NZ children
- Artificial intelligence retinal screening in NZ
- Mindfulness- and acceptance-based interventions for diabetes distress
- Egg consumption and risk of type 2 diabetes and coronary heart disease
- Mobile-based GDM management and *post partum* diabetes
- Trends in diabetes incidence
- Night-time heart rate variability and type 2 diabetes risk
- Glucose control, sulfonylureas and insulin in elderly type 2 diabetes
- CV and renal disease burden in type 1 vs. 2 diabetes
- Glucose contribution to HbA_{1c} and time in range in type 2 diabetes on insulin
- Therapeutic inertia in dyslipidaemia/hypertension management in incident type 2 diabetes

Abbreviations used in this issue

BP = blood pressure
CV = cardiovascular
GDM = gestational diabetes mellitus
HbA_{1c} = glycosylated haemoglobin
HR = hazard ratio
MI = myocardial infarction
OGTT = oral glucose tolerance test
RCT = randomised controlled trial

Welcome to issue 144 of Diabetes and Obesity Research Review.

We begin this issue with a randomised trial of one-step versus two-step screening (the latter being favoured in NZ) for detecting GDM (gestational diabetes mellitus) among expectant mothers. Another RCT has compared the effects of mobile versus standard management of women with GDM on *post partum* type 2 diabetes and its associated risk factors. There is also research reporting declining incidences of type 2 diabetes in many countries since 2010, which contrasts with the increasing prevalences (combination of new cases and longer survival) often cited. This issue concludes with trends in the prevalence of hypertension and dyslipidaemia in patients with incident type 2 diabetes, time to starting antihypertensive and lipid-lowering therapies, and associations with systolic BP and lipid control.

We hope you enjoy this update in diabetes and obesity research. We are always delighted to receive your comments and feedback.

Best regards,

Professor Jeremy Krebs

jeremykrebs@researchreview.co.nz

A pragmatic, randomized clinical trial of gestational diabetes screening

Authors: Hillier TA et al.

Summary: Pregnant women from one of two health systems (n=23,792) were randomised to one-step screening (fasting 75g OGTT) or two-step screening (nonfasting 50g OGTT followed if positive by a fasting 100g OGTT); the adherence rates for the respective groups were 66% and 92%. The proportion of participants diagnosed with GDM (primary endpoint) was greater in the one-step screening arm than in the two-step screening arm (16.5% vs. 8.5%; unadjusted relative risk 1.94 [97.5% CI 1.79, 2.11]), with no significant between-group difference for large-for-gestational-age infants (8.9% vs. 9.2%; 0.95 [0.87, 1.05]), a perinatal composite outcome of stillbirth, neonatal death, shoulder dystocia, bone fracture, or any arm or hand nerve palsy related to birth injury (3.1% vs. 3.0%; 1.04 [0.88, 1.23]), gestational hypertension or pre-eclampsia (13.6% vs. 13.5%; 1.00 [0.93, 1.08]) or primary caesarean section (24.0% vs. 24.6%; 0.98 [0.93, 1.02]).

Comment: Screening for GDM remains controversial. There are those who feel that GDM is not a major problem and is overdiagnosed, and screening should at most be targeted and opportunistic, and those who see GDM as a major problem for mother and child and advocate for universal screening. An OGTT is unpleasant and time consuming at the best of times, but even worse when you are pregnant (I'm told). Some countries use one-step screening with an OGTT, and others, NZ included, use a two-step process with a 50g nonfasted glucose challenge followed by a formal glucose tolerance test in those above a specific threshold. Even this differs between countries, with the US using a 100g glucose OGTT (yuk), whereas most use 75g. Furthermore, the cutoff for glucose level differs as well – a real pig's breakfast. This study reports the comparison between strategies with no major differences between them for maternal and perinatal outcomes. This is interesting, but I'm not sure how it specifically relates to the NZ chosen approach. It certainly doesn't suggest a strong need to change it.

Reference: *N Engl J Med* 2021;384:895–904

[Abstract](#)

NEW ZEALAND HAS A GROWING DIABETES PROBLEM¹

**WEIGHT LOSS HAS THE POTENTIAL TO INDUCE REMISSION OF TYPE 2 DIABETES IN PEOPLE WHO ARE OVERWEIGHT OR OBESE.²
HELP YOUR PATIENTS MANAGE THEIR WEIGHT AND IMPROVE THEIR HEALTH.**

References: 1. A rising tide of type 2 diabetes in younger people: what can primary care do? BPAC. [Online]. Accessed: <https://bpac.org.nz/2018/docs/diabetes.pdf>. 2. Lean M. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial 2017; [http://dx.doi.org/10.1016/S0140-6736\(17\)33102-1](http://dx.doi.org/10.1016/S0140-6736(17)33102-1). **DUROMINE™** IS A C5 CONTROLLED DRUG. **DUROMINE™** IS AN UNFUNDED MEDICINE - A PRESCRIPTION CHARGE WILL APPLY. PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING AVAILABLE AT WWW.MEDSAFE.GOV.NZ OR PHONE Freephone 0508 375394. Minimum Data Sheet Information (phentermine). **DUROMINE™ Indications:** For the management of obesity as a short-term adjunct in a medically monitored weight loss programme based on exercise, diet and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m² or greater. **DUROMINE™** may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. **Dosage and Administration:** The usual starting dose in adults and children over 12 years is 30 mg once daily at breakfast. Continuous or intermittent maintenance dose is 15 mg to 30 mg once daily depending on responsiveness. Patients require medical review after a defined course of treatment, which should not exceed three months. Available in 15 mg and 30 mg capsules. **Contraindications:** Pulmonary artery hypertension, heart valve abnormalities, heart murmurs, moderate to severe hypertension, cerebrovascular disease, severe cardiac disease including arrhythmias, advanced arteriosclerosis, hypersensitivity to sympathomimetic drugs, hyperthyroidism, psychiatric illnesses, glaucoma, drug/alcohol abuse or dependence, concomitant MAOIs or within 14 days of MAOI use. **Precautions:** Short term monotherapy only. Co-administration of drug products for weight loss is not recommended. There have been no reported cases of valvular heart disease occurring with phentermine alone. Use with caution in mild hypertension, established coronary artery disease, epilepsy, and in those receiving insulin, oral hypoglycaemic agents or psychotropic agents. **Adverse Effects:** The most common are palpitations, tachycardia, elevation of blood pressure and precordial pain. Others included restlessness, insomnia, nausea, and dry mouth. Psychotic episodes, hallucinations and serious cardiovascular or cerebrovascular events are rare. Full Data Sheet and Consumer Medicine Information is available from Medsafe at www.medsafe.govt.nz. (Novo Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067, Australia. Distributed in New Zealand by Radiant Health Ltd, c/o Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. For all product enquiries: New Zealand Toll Free: 0508 375 394. TAPS NA 12719. NZ2021-02-0010. February 2021.



For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication



Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

NEW. For your patients with type 2 diabetes[†]

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{†1,2}

Click below to download your JARDIANCE resources

PRESCRIBING GUIDE **PATIENT BOOKLET**

Pre-diabetes prevalence and associated factors in New Zealand school children

Authors: Mazahery H et al.

Summary: Relationships between selected factors and prediabetes were explored in 451 children from the cross-sectional Auckland Children's Bone Study stratified as normoglycaemic (HbA_{1c} level ≤39 mmol/mol) or prediabetic (HbA_{1c} level >39 mmol/mol). Prediabetes was present in 16% of the children overall, with higher rates in South Asian, Pacific Island and Māori children compared with European children (30%, 27% and 18%, respectively, vs. 6.0% [p<0.001]). Among children of South Asian and Pacific Island ethnicity, factors associated with prediabetes were high waist circumference, high percentage bodyfat and low physical activity.

Comment: These are really important and useful data on prediabetes in NZ children. We all know and see an increase in diabetes in young people. This is a major concern, because to date, children and young adults with type 2 diabetes do not do well. They have worse glycaemic control and earlier onset of complications compared with older adults who develop type 2 diabetes. Prediabetes is a precursor to type 2 diabetes, and whilst we debate the rate of progression and whether prediabetes defined by HbA_{1c} level carries the same risk as if diagnosed by an OGTT, the figures shown in this study remain concerning. Furthermore, they mirror the differences between ethnicities seen in adults, and once again illustrate the inequities in health in NZ. We need to better understand how we can turn this around to reduce progression to full type 2 diabetes at both individual and population levels.

Reference: N Z Med J 2021;134(1531):76–90

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

NZMA
New Zealand Medical Association

Rotorua GP CME
General Practice Conference & Medical Exhibition

10-13 JUNE 2021
ENERGY EVENTS CENTRE
ROTORUA

[gpcme.co.nz](#)

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).^{‡2}
*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. [†]In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. [‡]The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. N Engl J Med. 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy:* When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy:* With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m² or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (NZ) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370



Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461



Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
N7BN 0470070550642

For more information, please go to www.medsafe.govt.nz



Saxenda®
liraglutide (lys)

*I have the will to train
three times a week. But I
still need help to lose
weight and keep it off.*

MICHAEL; Age: 38 BMI: 34
Patient portrayal



Visit SAXENDACARE.CO.NZ to learn more
Click below to download your Saxenda® resources

PRESCRIBING GUIDE

PATIENT BOOKLET

Saxenda® is an unfunded prescription medicine. Doctor's fees and pharmacy charges may apply. Please review Data Sheet before prescribing. The Data Sheet can be accessed at www.novonordisk.co.nz

SAXENDA® (liraglutide (lys) 6 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of ≥ 30 kg/m² (obese) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight. **Dose/administration:** Administered subcutaneously once daily at any time, independent of meals; starting dose 0.6 mg/day; increase to 3.0 mg/day in increments of 0.6 mg per week. If escalation to the next dose is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended. Must not be administered intravenously or intramuscularly. **Contraindications:** Hypersensitivity to liraglutide or any of its excipients. **Warnings/Precautions:** Not for use in patients: with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain; children (<18 years); with a history of pancreatitis, severe renal impairment including end-stage renal disease, hepatic impairment or insufficiency, inflammatory bowel disease or diabetic gastroparesis; ≥ 75 years. Must not be used as a substitute for insulin. Should not be used: with insulin; in combination with other prescription, over-the-counter or complementary medicines intended for weight loss. Use with caution in patients: 65-74 years; with thyroid disease; on other drugs that increase heart rate. Advise patients of the potential risk of dehydration in relation to gastrointestinal side effects and to take precautions to avoid fluid depletion. If pancreatitis is suspected, treatment should be discontinued and appropriate management initiated. If acute pancreatitis is confirmed, Saxenda® should not be restarted. A higher rate of cholelithiasis and cholecystitis has been observed in patients treated with Saxenda® - patients should be informed of the characteristic symptoms. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Saxenda® should be discontinued for patients who experience a sustained increase in resting heart rate. Reducing the dose of concomitantly administered insulin secretagogues to reduce the risk of hypoglycaemia should be considered. Pregnancy Category B3. Not for use during pregnancy or breast-feeding. **Undesirable effects:** Very Common: nausea, vomiting, diarrhoea, constipation. Common: dyspepsia, abdominal pain upper, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, dry mouth, gastritis, hypoglycaemia, injection site reactions, fatigue, asthenia, dizziness, dysgeusia, cholelithiasis, insomnia, increased lipase, increased amylase. (January 2020).

Novo Nordisk Pharmaceuticals Ltd., G.S.T. 53 960 898. PO Box 51268
Pakuranga, Auckland, New Zealand. NovoCare® Customer Care Center (NZ) 0800 733 737.
www.novonordisk.co.nz. © Registered trademark of Novo Nordisk A/S. ANZ20S00065.
TAPS BG1054. Prepared: March 2021.



For more information, please go to www.medsafe.govt.nz

THEIA™ development, and testing of artificial intelligence-based primary triage of diabetic retinopathy screening images in New Zealand

Authors: Vaghefi E et al.

Summary: These NZ authors reported on the development and evaluation of THEIA™, an artificial intelligence system for detecting diabetic retinopathy and maculopathy. Development of THEIA used routinely collected data from 32,354 consecutive individuals with diabetes who underwent 63,843 retinal screens within the Auckland and Counties Manukau DHBs. Most screening results (95–97%) were categorised as non-sight-threatening, with 0.9–2.4% and 1.1–3.1% categorised as potentially referable and sight-threatening, respectively. Using the referable/nonreferable categories, the respective sensitivity and specificity values for THEIA were 94% and 63% for the Auckland DHB dataset, and 95% and 61% for the Counties Manukau DHB dataset. It was concluded that the manual grading load associated with retinal screening of diabetics could be significantly reduced if THEIA was incorporated into NZ's diabetic screening programme.

Comment: Retinal screening for retinopathy in people with diabetes is something that lends itself to a more automated approach. A retinal screening programme is highly effective in reducing the incidence and severity of proliferative retinopathy and blindness. However, it is very user dependant and personnel heavy, and always prone to human error. Because patients have serial scans over time, with stored digital images, it is an ideal situation for artificial intelligence to be used to train a computer to read scans and identify individuals at risk. This NZ research demonstrates the effectiveness of this approach. This could make a real difference if it can be implemented across the country, and could be particularly useful in smaller and rural centres – great stuff.

Reference: *Diabet Med* 2021;38:e14386

[Abstract](#)

Effects of mindfulness- and acceptance-based interventions on diabetes distress and glycaemic level in people with type 2 diabetes

Authors: Ngan HY et al.

Summary: This was a systematic review and meta-analysis of nine RCTs (n=801) reporting on the effects of acceptance and commitment therapy, mindfulness-based cognitive therapy, mindfulness-based stress reduction or self-directed mindfulness practice in adults with type 2 diabetes; most of the study participants had an HbA_{1c} level of > 53 mmol/mol. Compared with control groups, the interventions were associated with reductions in diabetes distress ($p < 0.01$) and HbA_{1c} level ($p = 0.03$) up to 1 month postintervention; however, underpowered studies may have resulted in overestimation; the interventions for both outcomes were heterogeneous.

Comment: Diabetes distress is something I think about mostly in those with type 1 diabetes, particularly in the young adult group; however, it is clear that it does occur in all groups with all forms of diabetes. It is a common reason for or contributor to sudden jumps in HbA_{1c} level or persistently elevated HbA_{1c} levels. Recognising this and acknowledging it is the first major step for both patient and clinician alike. However, reducing diabetes distress can be difficult, and requires a lot of input and time for all. This systematic review and meta-analysis looked at the effect of different interventions on distress and glycaemic control. Whilst there are positive effects, the reduction in HbA_{1c} level is modest overall, and it is hard to know what the difference in the distress score actually translates to in people's experiences and quality of life.

Reference: *Diabet Med* 2021;38:e14525

[Abstract](#)

RACP MyCPD Program participants can claim one credit per hour (maximum of 60 credits per year) for reading and evaluating Research Reviews.

FOR MORE INFORMATION [CLICK HERE](#)

Egg consumption, overall diet quality, and risk of type 2 diabetes and coronary heart disease

Authors: Djoussé L et al.

Summary: These researchers assessed the impact of egg consumption on the risks of type 2 diabetes and coronary heart disease after adjustment for overall diet using data pooled from nine prospective US cohorts (n=103,811). Most of the cohorts had median egg consumption of 1 egg per week. The risk of type 2 diabetes was not increased by consumption of ≤ 1 egg per week, but consumption of ≥ 2 eggs per week did increase the risk, with ≥ 7 vs. 0 eggs per week increasing the risk by 27%. Although there was no overall association between egg consumption and coronary heart disease risk, sensitivity analyses detected there was a 30% increase in risk for older adults who consumed 5–6 eggs per week.

Comment: The humble egg gets mixed reviews when it comes to whether it is a healthy choice or not. Eggs are an easy food choice for quick meals, particularly for those adopting a low-carbohydrate diet. However, concerns have been raised over the risk for CV disease, especially in those with dyslipidaemia. This study reports on pooled data from nine cohort studies on the association between egg consumption and incident diabetes or CV disease, and tries to account for confounding factors. I was surprised to see that weekly consumption of more than one egg increased the risk of diabetes but not CV disease. It was only in an exploratory analysis that it appears that older adults with a high intake of eggs may be at more risk, but in the absence of a primary effect, this must be seen with caution. It is the greater incidence of type 2 diabetes that is of concern and needs further study and understanding.

Reference: *Clin Nutr*; Published online March 10, 2021

[Abstract](#)

Effect of mobile health based peripartum management of gestational diabetes mellitus on postpartum diabetes

Authors: Huang F et al.

Summary: In this trial, 309 women with GDM were randomised to receive standard management or mobile management, and 75g OGTTs were performed at 6 weeks *post partum*. Compared with standard management, mobile management was associated with a higher incidence of type 2 diabetes *post partum* (12.36% vs. 3.88% [$p=0.0291$]). In the mobile management group, women with type 2 diabetes had significantly higher fasting, 1-hour and 2-hour OGTTs at 24–28 weeks' gestation than those without type 2 diabetes, and in the standard management group, the 1-hour and 2-hour OGTTs at 24–28 weeks' gestation were significantly higher among women with type 2 diabetes. A higher OGTT at 24–28 weeks' gestation was a risk factor for type 2 diabetes *post partum*.

Comment: The concept of using mobile technologies for improving health outcomes seems very logical and has been studied in many situations. In diabetes, the results have been very mixed, but largely underwhelming. Most studies have not shown a benefit of mobile apps, text message prompting or similar on weight, glucose control or other outcomes. This study explored mobile management for women with GDM after delivery to try to reduce the risk of developing type 2 diabetes. Once again, it seems likely to be helpful by reducing time burden on a busy new mum. However, it actually increased risk compared with standard in-person care. We must be very careful not to assume that because technology can reduce the burden of care that it will necessarily improve outcomes. This is exactly why we need well-designed RCTs.

Reference: *Diabetes Res Clin Pract* 2021;175:108775

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

Choose to add in Lantus® for Type 2 Diabetes patients with an HbA1c of $>53\text{mmol/mol}$ ^{1,2#}

Reasons to use Lantus®.

Lantus® once-daily in Type 2 Diabetes³:

- Has proven efficacy in reducing HbA1c³⁻⁵
- Is associated with a lower risk of hypoglycaemia compared with NPH^{6-8*}
- Is easy to initiate and for patients to self titrate⁹

*After lifestyle and oral diabetes medication optimisation. The target HbA1c in most patients with diabetes is $< 53\text{mmol/mol}$ ^{1,2}
#Excluding severe hypoglycaemia



References: 1. Melanie J. Davies et al. *Diabetes Care* 2018; 41:2669-2701. Reference 2. Type 2 diabetes Management Guidance. NZSSD. 2021. 3. Lantus Data Sheet. 31 July 2017. 4. DeVries J H. *Eur Endocrinol* 2014;10(1):23-30. 5. Gerstein HC, et al. *N Engl J Med* 2012;367:319-28. 6. Bazzano L A, et al. *Diabetic Medicine* 2008;25:924-932. 7. Horvath K, et al. Long acting insulin analogues vs NPH insulin (Human isophane insulin) for Type 2 Diabetes Mellitus. *Cochrane Review* 2009. 8. Home P D, et al. *Diabetes, Obesity and Metabolism*. 2010; 12:772-779. 9. Davies M et al. *Diabetes Care*. 2005; 28:1282-88.

Lantus® Abridged Data Sheet

Please review Full Data Sheet before prescribing – available at www.medsafe.govt.nz or from the sponsor.

Lantus® (insulin glargine). **Indication:** Once-daily subcutaneous administration for type 1 and type 2 diabetes mellitus patients who require insulin for control of hyperglycaemia. **Contraindications:** Hypersensitivity to insulin glargine or any excipient. **Precautions:** Hypoglycaemia, possibly with delayed recovery or altered warning symptoms; hepatic, renal and visual impairment; lipodystrophy and other injection site or immediate-type allergic reactions; antibody production; not studied in children <6 years, pregnancy category B3, lactation; not intended for i.v. use; not recommended for treatment of diabetic ketoacidosis; LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. Patient instruction on intercurrent conditions, blood glucose monitoring, injection technique recommended. **Interactions:** Oral antidiabetic agents; cardiovascular, analgesic, anti-inflammatory, neurological, antipsychotic agents, antibiotics, corticosteroids, other hormonal therapies, diuretics, protease inhibitors, sympathomimetic agents, lithium, alcohol, sympatholytics including β -blockers, others. **Adverse effects:** Hypoglycaemia; injection site reactions; visual disturbances; others. **Dosage and Administration:** Subcutaneous, once daily; abdominal, thigh or deltoid administration; blood glucose monitoring is recommended. Lantus® is equipotent to human insulin. Initial dose should be determined individually, depending on desired blood glucose levels and doses and timing of any antidiabetic medication, including Lantus®. For changeover from once-daily NPH initial dose usually not changed; for changeover from twice-daily NPH to once-daily Lantus®, initial dose usually reduced by approximately 20% compared to total daily NPH dose; for initiation of type 2 patients, initial dose is usually approximately 10IU. For secondary dose adjustments, renal, hepatic impairment see full Data Sheet. **Medicine Classification:** Prescription Medicine. **Presentations:** Lantus® (insulin glargine injection) 100 U per mL is available in packs of 5x3mL cartridges, 5x3mL cartridges in SoloStar pre-filled pens and 10mL vials. **Sponsor:** Sanofi New Zealand, Level 8, 56 Cawley Street, Ellerslie, Auckland. Free phone 0800 283 684. Lantus® is a Funded Medicine. TAPS PP7259 MAT-NZ-210013. Date of preparation February 2021.

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication

Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings

Authors: Magliano DJ et al.

Summary: Changes in the incidence of clinically diagnosed diabetes (total and type 2) over time were examined using 24 population-based data sources from 19 high-income and two middle-income countries/jurisdictions. There were ~22 million diabetes diagnoses from 5 billion person-years of follow-up. Nineteen of 23 sources reporting data from 2010 onwards showed a downward or stable trend in the incidence of diabetes, with annual estimated incidence changes of -1.1% to -10.8%; the estimated changes were 0.9-5.6% for the four data sources that showed an increasing trend since 2010. The findings were robust to sensitivity analyses.

Comment: For a long time now we have been saying there is a type 2 diabetes epidemic with an ever-increasing prevalence year by year. In NZ, this has been in the order of 7% per annum over the last decade. What this paper points out is that prevalence is a combination of new cases and also longer survival. Therefore, understanding the incidence is also very important when considering whether efforts to turn this around are making any difference. This paper reports on data from multiple countries, using multiple sources over at least a decade. Whilst there are obvious confounders, such as definitions for diabetes and the increased use of HbA_{1c} level for diagnosis, the message is clear and surprising. The incidence of type 2 diabetes has plateaued and even turned downwards in many countries. If correct, this is very promising, but requires more investigation to be certain and more work to understand why and what factors have made the difference, so these can be focussed on further.

Reference: *Lancet Diabetes Endocrinol* 2021;9:203-11

[Abstract](#)

CLICK HERE

to read previous issues of
Diabetes & Obesity Research Review



South GP CME
General Practice Conference & Medical Exhibition

19-22 AUGUST 2021
HORNCastle ARENA
CHRISTCHURCH

gpcme.co.nz

Night-time heart rate variability identifies high-risk people among people with uncomplicated type 2 diabetes mellitus

Authors: Hadad R et al.

Summary: These researchers evaluated heart rate variability for predicting CV events in 653 community-dwelling individuals free of prior CV disease, including 133 with well-controlled or newly diagnosed type 2 diabetes. Over median follow-up of 14.4 years, overall there were 245 deaths and 149 CV events (36 CV-related deaths, 42 MIs, 46 revascularisation procedures and 70 strokes), including 41 CV events in the group with diabetes (13 CV-related deaths, 13 MIs, 17 revascularisation procedures and 18 strokes). In the group with type 2 diabetes, each 10 msec increment in the standard deviation for the mean value of normal-to-normal complexes in heart rate during the night was inversely associated with the risk of a CV event (adjusted HR 0.74 [95% CI 0.61, 0.89]); 24-hour heart rate variability was not associated with CV event risk, but was associated with all-cause mortality. The prediction of CV events by conventional risk factors was enhanced when night-time heart rate variability was added ($p=0.037$).

Comment: Autonomic neuropathy is likely under-recognised in people with diabetes. We are generally less tuned in to look for it, and tools like 24-hour heart rate monitoring have been relatively inaccessible in diabetes clinics. However, with the evolution of so many forms of personal health monitoring devices that readily capture all of these data, there is an opportunity to utilise this in clinical risk assessment. This study reports on the value of nocturnal heart rate variability in this context. It shows that the addition of this metric to traditional tools can identify individuals at high risk of CV events who would have otherwise been scored at low risk. This may become an important additional parameter to collect. It would be interesting to see how the addition of this to the PREDICT data in NZ would change the modelling.

Reference: *Diabet Med*; Published online March 13, 2021

[Abstract](#)

Glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes and risk of severe hypoglycemia and death

Authors: Ling S et al.

Summary: The risks of severe hypoglycaemia and mortality associated with glucose level control, sulfonylurea exposure and insulin treatment were explored in this observational study of 22,857 UK patients aged ≥ 70 years with type 2 diabetes. Individuals with three consecutive HbA_{1c} levels <53 mmol/mol while exposed to insulin and/or sulfonylureas within 60 days prior to the third HbA_{1c} level measurement ($n=6288$; 5659 exposed to a sulfonylurea) were matched to nonexposed individuals. During follow-up, the mortality and severe hypoglycaemic event rates were 47.6% and 6.1%, respectively, with insulin/sulfonylurea-exposed individuals at greater risk of severe hypoglycaemia (adjusted HR 2.52 [95% CI 2.23, 2.84]), but not CV- or non-CV-related mortality (0.98 [0.91, 1.06] and 1.05 [0.99, 1.11], respectively), than the nonexposed patients. The respective 10-year severe hypoglycaemic event risks for insulin/sulfonylurea-exposed patients aged 70, 75, 80 and 85 years were 7.7%, 8.1%, 8.6% and 8.4% greater than for nonexposed patients, whereas differences for non-CV mortality ranged from 1.2% in a 70-year-old to 1.6% in an 85-year-old. Sulfonylurea and insulin use had greater relevance for predicting severe hypoglycaemia and death than glucose level.

Comment: We often talk about the risk of hypoglycaemia with sulfonylureas and insulin therapy, particularly in the elderly. This is one of the reasons for supporting the use of newer diabetes drugs, which do not in themselves cause hypoglycaemia. This study is very helpful to quantify this risk. It is important to note that the patients included had tight glycaemic control. With that in mind, the HR for severe hypoglycaemia in over 70-year-olds was 2.5 for those on a sulfonylurea or insulin. This is important and highlights the need to avoid excessively tight glucose control in the elderly. However, the risk is almost certainly a great deal lower for those with an HbA_{1c} level above 60 mmol/mol, which let's face it, most of our patients are. As there is no evidence of increased mortality, the humble sulfonylurea may be getting an overly bad rap – particularly when it is cheap and pretty damn effective in lowering glucose levels.

Reference: *Diabetes Care* 2021;44:915-24

[Abstract](#)

Independent commentary by Professor Jeremy Krebs MBChB, FRACP, MD

Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He trained in Endocrinology at Wellington Hospital in New Zealand and then did his doctorate with the Medical Research Council - Human Nutrition Research unit in Cambridge England. His thesis was on the impact of dietary factors on obesity and insulin resistance. Professor Krebs returned to New Zealand in 2002 to take up a consultant Endocrinology post at Wellington Hospital, where he was Clinical Leader of Endocrinology and Diabetes. He heads the research group and is Professor with the University of Otago, and former Director of the Clinical Research Diploma at Victoria University - which he established. **FOR FULL BIO [CLICK HERE](#).**





Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes

Authors: Kristófi R et al.

Summary: The risks of CV and renal disease were compared between cohorts of 59,331 adults with type 1 diabetes and 484,241 with type 2 diabetes from Sweden and Norway in this observational study with a mean 2.6 years of follow-up. Type 1 and type 2 diabetics had similar prevalences of CV disease across age strata, whereas those with type 1 diabetes had more chronic kidney disease. Compared with type 2 diabetes, type 1 diabetes was associated with increased risks of heart failure in patients aged 65–79 years (1.3- to 1.4-fold), MI in those aged 55–79 years (1.3- to 1.8-fold) and stroke in those aged 40–54 years (1.4- to 1.7-fold). Among patients with type 1 diabetes, the risk of chronic kidney disease was increased 1.4- to 3.0-fold at all ages, and the risk of death from any cause was increased 1.2- to 1.5-fold in those aged ≥50 years with a similar trend seen for CV-related death.

Comment: A recent publication showed that life expectancy for people with type 1 diabetes is still about 10 years lower than for those without diabetes. It is easy to forget this, particularly when working with young people. This current paper from Scandinavia using registries of patients with diabetes clearly demonstrates that people with type 1 diabetes actually have greater risk for CV events and renal disease than those with type 2 diabetes. It is a poignant reminder that we need to aggressively manage cardiac risk factors in people with type 1 diabetes, although I still struggle with the timing of introducing statin therapy.

Reference: *Diabetes Care*; Published online March 2, 2021

[Abstract](#)

Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy

Authors: Liao B et al.

Summary: Using pooled data from five insulin lispro trials, these researchers explored inter-relations between glycaemic metrics in 1572 recipients of basal-bolus or basal-plus insulin for type 2 diabetes. A 1 mmol/L change in fasting plasma glucose level was associated with a 2.7 mmol/mol change in HbA_{1c} level ($p < 0.0001$), a 1 mmol/L change in postprandial glucose level was associated with a 1.8 mmol/mol change in HbA_{1c} level ($p < 0.01$), and 1 mmol/L reductions in fasting plasma and postprandial glucose levels were associated with increased times in target range of 6.5% and 5.3%, respectively ($p < 0.0001$). On average, an HbA_{1c} level reduction of 10.9 mmol/mol corresponded with an 8.3% increase in time in target range.

Comment: The relative contribution of fasting versus postprandial glucose level to overall glycaemic burden and HbA_{1c} level is often debated. This study adds somewhat to that question. It used pooled data from pharmaceutical company trials of people with type 2 diabetes on insulin therapy. Although useful, the main limiting feature of this study is the reliance on capillary glucose monitoring. It is clear from continuous glucose monitoring that using an isolated 2- or 3-hour postprandial measurement is relatively crude compared with the more dynamic data and ability to use the area under the curve from continuous glucose monitoring. Nevertheless, it highlights that we need to focus on both the fasting and postprandial periods to achieve a good HbA_{1c} level. What it doesn't tell us is whether postprandial hyperglycaemia has an independent and additional association with adverse outcomes.

Reference: *Diabetes Obes Metab*; Published online March 9, 2021

[Abstract](#)

Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden

Authors: Ling JZJ et al.

Summary: Trends in the prevalences of hypertension and dyslipidaemia in incident type 2 diabetes, times to antihypertensive and lipid-lowering therapies and associations with systolic BP and lipid control were reported for 254,925 real-world primary-care patients from the UK with incident type 2 diabetes and existing dyslipidaemia (66%) or hypertension (66%). During 2005–2016, the prevalence of dyslipidaemia increased by 10% in patients aged <60 years while the prevalence of hypertension remained stable across all age groups. Among patients aged 18–39, 40–49 and 50–59 years who were at high risk of atherosclerotic CV disease, the respective median numbers of months to initiation of therapy were 20.4, 10.9 and 9.5 among those with dyslipidaemia, and 28.1, 19.2 and 19.9 among those with hypertension. For the respective high and low atherosclerotic CV disease risk groups, those who started lipid-lowering therapy after 1 year versus earlier had 65.3–85.3% and 65.0–85.3% higher likelihoods of failing lipid control after 2 years, and those who started antihypertensive therapy late had 46.5–57.9% and 40.0–58.7% significantly greater probabilities of failing systolic BP control.

Comment: Clinical inertia can be a major problem in the management of chronic disease. It is clearly seen in the delay to initiation of insulin therapy in type 2 diabetes prior to the expansion of our toolbox of oral agents, when people would be on maximal oral therapy with a rising HbA_{1c} level for well over 12 months before insulin initiation. Those studies highlighted the shared responsibility for this between clinicians and patients. Lipid and BP management are somewhat different issues. First the therapies are all oral medications, but second, whilst there is clear evidence for BP and lipid lowering in secondary prevention, there remain uncertainties for primary prevention. Do you look at risk factors in isolation and treat them accordingly, or do you conduct an overall risk assessment and base both interventions on that? We tend to favour the latter in NZ. Either way this paper highlights the high proportion of patients who have risk factors above recommended levels at the time of diabetes diagnosis.

Reference: *Diabetes Obes Metab*; Published online March 2, 2021

[Abstract](#)

ADC
AUSTRALASIAN
DIABETES CONGRESS 2021

Brisbane Convention
and Exhibition Centre
11 – 13 August 2021

ads
Australian Diabetes Society

ADEA
New Zealand partners in diabetes care



Kindly Supported by

